Published

J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis - Pharmaceutical Technology

Summary by Pharmaceutical-technology.com
Johnson & Johnson Innovation Medicine has submitted a request to the FDA to approve Tremfya as a treatment for ulcerative colitis.
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)